Roger M Lane

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Acetylcholinesterase and its inhibition in Alzheimer disease
    Roger M Lane
    Novartis Neuroscience, Novartis Pharmaceuticals Corp, East Hanover, NJ 07936 1080, USA
    Clin Neuropharmacol 27:141-9. 2004
  2. ncbi Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences
    Murat Emre
    Department of Neurology, Istanbul Faculty of Medicine, Istanbul, Turkey
    J Alzheimers Dis 11:509-19. 2007
  3. doi Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease
    Roger Lane
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 1080, USA
    Pharmacogenet Genomics 18:289-98. 2008
  4. doi BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline
    Roger Lane
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 1080, USA
    Mov Disord 24:392-400. 2009
  5. doi Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon 4, and hyperhomocysteinemia in neurodegenerative dementias
    Roger M Lane
    Novartis Neuroscience, Novartis Pharmaceuticals Corporation, 59 Route 10, East Hanover, NJ 07936 1080, USA
    Med Hypotheses 73:230-50. 2009
  6. ncbi Targeting acetylcholinesterase and butyrylcholinesterase in dementia
    Roger M Lane
    Novartis Neuroscience, Novartis Pharmaceuticals Corporation, NJ, USA
    Int J Neuropsychopharmacol 9:101-24. 2006
  7. ncbi Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease
    Roger M Lane
    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    J Lipid Res 46:949-68. 2005

Detail Information

Publications7

  1. ncbi Acetylcholinesterase and its inhibition in Alzheimer disease
    Roger M Lane
    Novartis Neuroscience, Novartis Pharmaceuticals Corp, East Hanover, NJ 07936 1080, USA
    Clin Neuropharmacol 27:141-9. 2004
    ..If such differences between ChE-Is are shown to have clinical correlates, this may prompt reconsideration of the rationale and expectations of some agents in the long-term management of AD...
  2. ncbi Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences
    Murat Emre
    Department of Neurology, Istanbul Faculty of Medicine, Istanbul, Turkey
    J Alzheimers Dis 11:509-19. 2007
    ..In both populations, hallucinations may identify patients who are likely to be more treatment-responsive...
  3. doi Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease
    Roger Lane
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 1080, USA
    Pharmacogenet Genomics 18:289-98. 2008
    ..To evaluate the synergistic effects of the apolipoprotein E (APOE) epsilon4 and butyrylcholinesterase K-variant (BCHE-K) alleles on progression to Alzheimer's disease (AD) in individuals with mild cognitive impairment (MCI)...
  4. doi BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline
    Roger Lane
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 1080, USA
    Mov Disord 24:392-400. 2009
    ..These results suggest that genetic and biochemical risk factors for AD and PDD pathology may be important in dementia onset and progression in these Lewy body disorders...
  5. doi Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon 4, and hyperhomocysteinemia in neurodegenerative dementias
    Roger M Lane
    Novartis Neuroscience, Novartis Pharmaceuticals Corporation, 59 Route 10, East Hanover, NJ 07936 1080, USA
    Med Hypotheses 73:230-50. 2009
    ....
  6. ncbi Targeting acetylcholinesterase and butyrylcholinesterase in dementia
    Roger M Lane
    Novartis Neuroscience, Novartis Pharmaceuticals Corporation, NJ, USA
    Int J Neuropsychopharmacol 9:101-24. 2006
    ....
  7. ncbi Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease
    Roger M Lane
    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    J Lipid Res 46:949-68. 2005
    ..This review examines the current evidence for diet, lipid homeostasis, and apoE in the pathogenesis of AD. Effects on the cholinergic system and response to cholinesterase inhibitors by APOE allele carrier status are discussed briefly...